Lamid is a new antifungal drug which can be administered orrally and is effective against a broad range of dermatomycoses. This report summarizes its mycological and clinical cure rates in 32 clinical studies in which it was used orally for the treatment of tinea corporis, tinea pedis (both interdigital and plantar types), onychomycosis of fingernails and toenails, cutaneous candidiasis and pityriasis versicolor. The pharmacokinetic profile shows Lamisil to be distributed extensively into lipophilic tissue and to have an elimination half-life from plasma which allows effective oncedaily administration. It diffuses from the vascular system into the stratum corneum where it binds, reaching levels well above the fungicidal concentrations against dermatophytes and yeast. In the treatment of over 1000 patients it has been shown to be very effective, leading to clinical cure in all the dermatomycoses listed above except pityriasis versicolor. It was particularly, and uniquely, effective in the most chronic forms of tinea pedis and onychomycosis. Lamisil is well tolerated, with only mild to moderate transient gastrointestinal side effects such as fullness, dyspepsia or nausea in a few patients. None of the hepatic or endocrine effects seen with imidazoles has been observed. Animal toxicology issues are reviewed. Lamisil meets a need for a new class of antifungal drug which is well tolerated, has rapid onset of action, can be used for short durations of therapy, is fungicidal and is active against chronic, resistant forms of dermatophyte infections of skin and nails.